Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of simtuzumab (GS-6624) in compensated NASH cirrhosis
2012-002489-11Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis and metabolic dysfunction-associated steatohepatitis (MASH) comparing Simtuzumab dose-ranging with Placebo (2 arms). Started Jan 2013; status: terminated.
02
Drugs
simtuzumab
03
Conditions
Cirrhosismetabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2012-002489-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002489-11.